The Robert Packard Center for ALS Research at Johns Hopkins and ALS United will fund a preclinical study investigating how TDP-43 abnormalities contribute to amyotrophic lateral sclerosis (ALS). The project, “Alternative Polyadenylation-Driven Subcellular RNA Mislocalization in TDP-43 Proteinopathies,” will explore the molecular mechanisms by which TDP-43 clumps,…
Former Texas A&M University football player Chris Larkin is returning to the university’s campus in College Station, widely known as Aggieland, to rally support in the fight against amyotrophic lateral sclerosis (ALS). Larkin, who played tight end for the Texas A&M Aggies in the 1980s, was diagnosed with…
The first participant has been enrolled in a large Italian clinical trial that’s testing Avextra’s cannabis-based medicine for managing symptoms in people with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The NEUROBIS Phase 2 study was cleared to start about a year ago by both the Italian…
People with amyotrophic lateral sclerosis (ALS) spend upward of $47,000 on medical care during the first year after their diagnosis, more than three times the amount spent by the average Medicare user, according to a new study by the ALS Association. The study results further showed that so-called…
A new blood test that analyzes tiny fragments of DNA released by dying cells may help diagnose amyotrophic lateral sclerosis (ALS) and predict how quickly the disease will progress, a study suggested. “Our model test could not only distinguish ALS patients from healthy individuals but also from those with other…
The ALS Association has launched the ALS Focus Data Dashboard, a free interactive tool that gives researchers, clinicians, and the public access to five years of self-reported clinical, demographic, and socioeconomic data from more than 4,000 people with amyotrophic lateral sclerosis (ALS) and their caregivers across the U.S.
Researchers in the U.S. and Europe have identified a number of novel blood and spinal fluid biomarkers that could help track amyotrophic lateral sclerosis (ALS) progression and monitor patient responses to therapeutic interventions, a new study reports. Several of the proteins found altered in people with ALS versus healthy…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to CK0803, a regulatory T-cell therapy being developed by Cellenkos for amyotrophic lateral sclerosis (ALS), with a goal of slowing disease progression. The FDA designation is intended to accelerate the development and review of new treatments…
Amyotrophic lateral sclerosis (ALS) is more common in some parts of the U.S. than others, and it has a very strong geographic association with multiple sclerosis (MS), a new study suggests. The finding implies that some type of environmental factors may be increasing the risk of both…
Bristol Myers Squibb is extending a research collaboration with the artificial intelligence company Insitro to design new medicines against a novel target in amyotrophic lateral sclerosis (ALS). The target was identified during the previous five-year agreement between the companies, which aimed to discover new molecules that could…
